Seeing further.


We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

EXTON, Pa. and CAMBRIDGE, Mass. , March 07, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

- Clinical trial targeting enrollment of approximately 300 anti-PD-1 refractory melanoma patients… Read more 

BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger

Read more 

Learn More


Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More